BackgroundBrain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). The treatment of brain metastasis in patients with ALK-positive NSCLC requires a multidisciplinary approach. including targeted therapy. chemotherapy. https://smokeysmountainfurnitureoutlets.shop/product-category/mirror-2/